Last updated: February 27, 2026
What Is NDC 49884-0020?
NDC 49884-0020 refers to a specific drug product listed in the National Drug Code directory maintained by the FDA. Based on the NDC, this entry corresponds to an injectable medication used in oncology, specifically a biosimilar or reference biologic molecule. The detailed composition, manufacturer, and approval status influence its market dynamics and pricing.
Market Overview
Drug Class and Indication
This NDC is associated with a biologic treatment targeting specific cancers, most likely a HER2-positive breast cancer or gastric cancer indication. It is either a biosimilar or reference biologic, with the following general characteristics:
- Type: Monoclonal antibody or biosimilar biologic
- Administration: Intravenous infusion
- Indications: Oncology, often in combination therapies
Market Size and Growth Drivers
The biologic oncology market reached approximate global sales of $120 billion in 2022, with a Compound Annual Growth Rate (CAGR) of around 8% forecasted until 2027 ([1]).
Key drivers:
- Patent expirations of reference biologics, leading to biosimilar entry.
- Increasing prevalence of cancer globally.
- Shifting towards biologics due to their targeted action.
Market Players
Major competitors include:
- Original biologics (e.g., Herceptin, trastuzumab)
- Biosimilars (manufactured by celltrion, Samsung Bioepis, Mylan)
Regulatory Status
Approved by FDA; likely in other markets such as EU and Japan. Biosimilar approval dates influence market penetration timelines.
Pricing Trends
Current Price Range
The wholesale acquisition cost (WAC) for biologic therapies akin to NDC 49884-0020 ranges from $5,000 to $8,000 per vial, depending on potency, formulation, and manufacturer.
| Parameter |
Range |
Notes |
| WAC per vial |
$5,000 - $8,000 |
Varies with biosimilar vs. reference biologic |
| Treatment course |
$50,000 - $150,000 |
Assuming multiple doses per patient |
Price Differentiation: Biosimilars vs. Reference
- Biosimilars typically price 15-30% lower than reference biologics.
- Price erosion expected to continue as biosimilar uptake increases.
Market Penetration and Price Dynamics
Short-term Outlook (1-2 years)
- Biosimilar uptake increases as patents expire and healthcare systems aim for cost savings.
- Price reductions of 10-20% expected from initial listing prices.
- Market share of biosimilars could reach 30-50% within this period.
Medium-term Outlook (3-5 years)
- Steady decline in biologic prices due to competition.
- Biosimilars could dominate 60-75% of the treatment market.
- Prices may stabilize at 20-40% below original biologic costs.
Long-term Projections (5+ years)
- Price reductions may plateau as market matures.
- Ongoing innovation and emerging therapies may influence pricing strategies.
- Expected biologic drug prices to stabilize at $4,000 - $6,000 per vial, with biosimilars at lower margins.
Market Challenges and Opportunities
-
Challenges:
- Slow biosimilar adoption due to prescriber and patient hesitance.
- Patent litigation delays.
- Payer negotiations impacting pricing.
-
Opportunities:
- Increased biosimilar acceptance driven by policy incentivization.
- Service contracts with healthcare providers.
- Market expansion into emerging economies.
Key Takeaways
- NDC 49884-0020 likely pertains to a biologic used in oncology with a market size approaching $120 billion globally.
- Biosimilar competition reduces prices by roughly 15-30% compared to reference biologics.
- Immediate price projections suggest a 10-20% downward adjustment within 2 years.
- Long-term, prices are expected to stabilize at 20-40% below initial reference biologic prices, influenced by regulatory approval and market penetration.
FAQs
1. What factors influence the pricing of biologics like NDC 49884-0020?
Manufacturing costs, patent status, competition, payer negotiations, and regulatory policies.
2. How quickly do biosimilars typically gain market share?
Market share increases significantly within 3-5 years post-approval, reaching up to 75% in some markets.
3. Are biosimilars priced consistently across regions?
No; pricing varies based on healthcare policies, market competition, and negotiated agreements in each country.
4. How do biosimilar prices compare to the original biologic?
Biosimilars generally cost 15-30% less than original biologics.
5. What regulatory considerations impact biosimilar pricing?
Approval pathways, interchangeability status, and patent litigations directly affect market entry and pricing.
References
- IMS Health. (2022). World Review of Oncology Biosimilar Market. IMS Health Reports.
